Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Odalasvir, AL-335, and Simeprevir in Healthy Japanese Subjects
NCT02824315Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adafosbuvir and odalasvir in hepatitis C (HCV), sponsored by Janssen Pharmaceutical. Primary endpoints: Average Analyte Concentration at Steady State, Maximum Observed Analyte Concentration and 9 more. Started May 2016; status: completed.
02
Drugs
adafosbuvirodalasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02824315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02824315.